March 6, 2018 / 1:41 PM / 3 months ago

BRIEF-Bavarian Nordic: Additional Positive Data From Phase 2 Study

* REG-BAVARIAN NORDIC ANNOUNCES ADDITIONAL POSITIVE DATA FROM A PHASE 2 STUDY OF ITS UNIVERSAL RSV VACCINE

* SAYS TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM ITS 421 PATIENT

* ‍PRESENCE OF ANTIBODIES IN NASAL MUCOSA SUGGEST VACCINE-INDUCED IMMUNE PROTECTION AT SOURCE OF INFECTION​

* ‍IGA ANTIBODIES AGAINST RSV OBSERVED IN BOTH SERUM AND MUCOSA OF VACCINATED INDIVIDUALS​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below